A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Clinical Trial ID NCT01083615

PubWeight™ 15.59^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01083615

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Novel therapies for metastatic castrate-resistant prostate cancer.	J Natl Cancer Inst	2011	1.98
2	Drug resistance in metastatic castration-resistant prostate cancer.	Nat Rev Clin Oncol	2010	1.86
3	Validation and clinical utility of prostate cancer biomarkers.	Nat Rev Clin Oncol	2013	1.17
4	Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.	Drug Des Devel Ther	2011	1.14
5	Overview of the latest treatments for castration-resistant prostate cancer.	Nat Rev Urol	2013	1.12
6	Overcoming drug resistance and treating advanced prostate cancer.	Curr Drug Targets	2012	0.95
7	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.	Prostate Cancer Prostatic Dis	2011	0.93
8	Overcoming docetaxel resistance in prostate cancer: a perspective review.	Ther Adv Med Oncol	2012	0.91
9	Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.	Oncologist	2011	0.90
10	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.	Int J Mol Sci	2013	0.88
11	Emerging molecularly targeted therapies in castration refractory prostate cancer.	Prostate Cancer	2013	0.83
12	The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer.	Ther Adv Urol	2014	0.83
13	Emerging targeted therapies for castration-resistant prostate cancer.	Front Endocrinol (Lausanne)	2012	0.81
14	Future directions in castrate-resistant prostate cancer therapy.	Clin Genitourin Cancer	2010	0.79
15	Abiraterone acetate: a hat trick of clinical benefits.	Lancet Oncol	2012	0.76